How can I manage insomnia that began after starting Spravato (esketamine nasal spray) for treatment‑resistant depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Managing Insomnia After Starting Spravato

Start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, as this is the evidence-based standard for managing insomnia disorder regardless of cause, while recognizing that insomnia is a documented side effect of esketamine that occurs in approximately 7% of patients. 1, 2, 3

Understanding the Problem

The FDA label explicitly lists insomnia as one of the symptoms that Spravato may produce, alongside anxiety, dysphoria, disorientation, and hallucinations 2. However, the clinical picture is nuanced: meta-analysis data shows that esketamine does not significantly increase the odds of treatment-emergent insomnia compared to placebo (OR = 1.07,95% CI 0.68-1.69) 3, and some studies even demonstrate that esketamine improves sleep disturbance scores more than placebo by day 8 of treatment 4.

This apparent contradiction likely reflects that:

  • Most TRD patients already have baseline sleep disturbance (65% moderate/severe, 25% mild) 4
  • Esketamine may paradoxically improve sleep in some while causing insomnia in others
  • Your insomnia may represent either a direct drug effect or inadequate depression response

Treatment Algorithm

Step 1: Assess Timing and Pattern

  • If insomnia started within the first 1-2 weeks: This may resolve spontaneously as many patients show sleep improvement by day 8 4
  • If insomnia persists beyond 2 weeks or worsens: Proceed with active intervention
  • Document: Sleep onset difficulty vs. sleep maintenance problems vs. early morning awakening

Step 2: Implement CBT-I (First-Line)

CBT-I is the gold-standard treatment with moderate-strength evidence for improving global sleep outcomes and most specific sleep parameters 1. This multicomponent approach includes:

  • Stimulus control: Use bed only for sleep and sex; leave bedroom if not asleep within 20 minutes
  • Sleep restriction: Limit time in bed to actual sleep time, then gradually increase
  • Cognitive restructuring: Address dysfunctional beliefs about sleep and catastrophizing
  • Relaxation training: Progressive muscle relaxation or breathing exercises
  • Sleep hygiene education: Consistent sleep schedule, avoid caffeine after noon, dark/cool bedroom

CBT-I typically requires 4-8 sessions with a trained therapist and shows sustained benefits beyond treatment completion 1.

Step 3: Consider Multicomponent Behavioral Therapy

If full CBT-I is not accessible, brief behavioral therapy for insomnia (combining sleep restriction, stimulus control, and relaxation without the cognitive component) has low-to-moderate strength evidence for improving sleep outcomes 1.

Step 4: Evaluate Esketamine Response

At 4 weeks (end of induction phase), assess whether esketamine is providing meaningful antidepressant benefit 2. This is critical because:

  • If depression is not responding adequately, the insomnia may reflect inadequate treatment
  • Evidence shows 1-point improvement in sleep at day 8 increases probability of antidepressant response by 26% and remission by 28% 4
  • Poor sleep response may predict poor overall treatment response

Step 5: Pharmacologic Considerations (Short-Term Only)

If behavioral interventions are insufficient and esketamine is otherwise effective for depression, short-term supplementary medication may be considered 1. However:

  • The American Academy of Sleep Medicine recommends psychological/behavioral interventions first, with only short-term supplementary medication 1
  • Pharmacologic options carry risks (cognitive/behavioral changes, falls, potential dependence) 5
  • This should be time-limited (weeks, not months) while behavioral interventions take effect

Step 6: Dosage Adjustment

Consider dose reduction from 84 mg to 56 mg if tolerability is the primary issue 2. The FDA label allows for dosage adjustment based on tolerability, and lower doses may reduce side effects while maintaining efficacy.

Critical Monitoring Points

  • Do not discontinue esketamine abruptly if it's providing depression benefit, as this may worsen both depression and potentially cause withdrawal symptoms with prolonged use 2
  • Reassess at week 4 and week 8: These are natural decision points in the esketamine protocol 2
  • Track both sleep and depression symptoms: Use sleep diaries (not polysomnography, which is not indicated) 1, 5

Common Pitfalls to Avoid

  1. Assuming all insomnia is drug-induced: Most TRD patients have baseline sleep disturbance that may improve with esketamine 4
  2. Jumping to sleep medications: This bypasses the most effective long-term treatment (CBT-I) 1
  3. Ignoring the 2-hour post-dose monitoring requirement: Ensure you're not engaging in activities that could worsen sleep hygiene after sessions 2
  4. Not addressing next-day sedation: Patients must avoid driving until after a restful sleep following each dose 2

When to Reconsider Esketamine

If insomnia is severe, persistent beyond 4-8 weeks, and esketamine is not providing meaningful depression benefit, discuss with your prescriber whether to:

  • Switch to alternative TRD treatments
  • Modify the dosing schedule (though evidence for this is limited)
  • Ensure concurrent oral antidepressant is optimized 2

The key principle: prioritize the treatment that addresses the life-threatening condition (treatment-resistant depression) while aggressively managing the insomnia with evidence-based behavioral interventions, not by reflexively discontinuing an effective antidepressant.

Related Questions

Can you provide comprehensive information on Spravato (esketamine) nasal spray, including its indications, dosing schedule, administration requirements, monitoring parameters, contraindications, and alternative treatment options?
Can a patient miss a dose of Spravato (esketamine) during the induction phase and still complete the induction?
Is a minimum 24‑hour interval required between Spravato (esketamine) doses during the induction phase?
How does zolpidem (Ambien) interact with esketamine?
What is the required minimum interval between Spravato (esketamine) treatment doses?
In a patient with Addison’s disease who takes hydrocortisone 15 mg in the morning and 10 mg in the evening at home, and oral hydrocortisone is unavailable inpatient, what alternative glucocorticoid regimen should be used?
In a postoperative patient with suspected gastric outlet obstruction on contrast CT showing an 18 mm pyloric opening and only trickling of contrast to the duodenum after two hours, with a nasogastric tube in place for gastric decompression, what is the next best step in management?
Why should enteric fever (typhoid) be treated for a full 14 days instead of a shorter course?
What is the interpretation and recommended next steps for spirometry results showing a forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio of 80%, FEV1 73% predicted, and FVC 69% predicted?
Can Tikosyn (dofetilide) be co‑administered with digoxin?
What is the appropriate evaluation and management of late‑onset diabetes in an adult who has undergone esophagectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.